Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05326516 · ClinicalTrials.gov registry record · Phase 1
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05326516 is a Phase 1 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT05326516, a Phase 1 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or NUP98r.
Interventions
- DRUG Revumenib
- DRUG Chemotherapy Regimen 1
- DRUG Chemotherapy Regimen 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2024-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05326516
The ClinicalTrials.gov registry entry for NCT05326516 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Revumenib is the first listed.
NCT05326516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05326516 about?
NCT05326516 is a clinical study titled "A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia". The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or NUP98r.
What is the current status of trial NCT05326516?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-03-09. Estimated completion is 2024-07-29.
What interventions are being tested in trial NCT05326516?
The interventions under investigation include: Revumenib (DRUG), Chemotherapy Regimen 1 (DRUG), Chemotherapy Regimen 2 (DRUG).
Who is sponsoring clinical trial NCT05326516?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.